PE 408 W

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CIV:

In re application of

Docket No: Q86824

Ikuya SEKI, et al.

Allowed: August 2, 2006

Appln. No.: 10/528,771

Group Art Unit: 1654

Confirmation No.: 2031

Examiner: David Lukton

Filed: March 23, 2005

For:

COMPOUND BINDING TO LEUKOCYTES AND MEDICINAL COMPOSITION

CONTAINING THE COMPOUND IN LABELED STATE AS THE ACTIVE

INGREDIENT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

· (2.56)

MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding September 22, 2006 Communication from a The Patent Office of the People's Republic of China, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/528,771

Atty. Docket No.: Q86824

A full copy of the reference, BAIDOO, K.E., et al., High-Affinity No-Carrier-Added

99mTc-Labeled Chemotactic Peptides for Studies of Inflammation in Vivo, Bioconjugate Chem.

1998 Mar-Apr; 9(2): 208-17, listed in the Information Disclosure Statement filed on

November 13, 2006 is now being submitted.

The present Information Disclosure Statement is being filed: (1) No later than three

months from the application's filing date; (2) Before the mailing date of the first Office Action

on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

CUSTOMER NUMBER

Date: November 14, 2006

2

, ,	1	• 4 '	7 200		MODIFIED PTO/SB/08 A & B (08	8-03)	
	(,	MOA 1 13	B	Complete if Known			
Substitute for Form 1449	A & B/PTO	A.	. Set Co	Application Number 10/528,771			
Substitute for Form 1449 A & B/PTO			MARI	Confirmation			
INFOR	MATION	DISCLO	SURE	Number	2031		
STATE	MENT BY	APPLIC	CANT	Filing Date	March 23, 2005		
hisa as	many shoo	ts as noco	ssarv)	First Named Inventor	Ikuya SEKI		
(use as many sheets as necessary)			isui y)	Art Unit	1654		
				Examiner Name	David Lukton		
G1 /	1	C	1	Attorney Docket			
Sheet		of	1	Number	Q86824		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document 1	Number	Publication Date			
		Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		US					
	-	US					
		US					
		US					
		US					
		US					
		US					
		US					
		US					

FOREIGN PATENT DOCUMENTS							
Examiner Cite Initials* No.1	Cite	Foreign Patent Document			Publication Date	Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
	 –						

	NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.				
		BAIDOO, K.E., et al., <u>High-Affinity No-Carrier-Added 99mTc-Labeled Chemotactic Peptides for Studies of Inflammation in Vivo</u> , Bioconjugate Chem. 1998 Mar-Apr; 9(2): 208-17.				

	 ·	 	T
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.